Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3515LS3W
Performance in the last:
Follow this Portfolio
1D 0.0 %
1W -0.9 %
2W 2.3 %
1M 8.0 %
3M 5.5 %
6M 16.9 %
9M 4.7 %
1Y -67.1 %
Alpha
-81.6%
Beta
0.66
sharpe-R
-0.94
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.8
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-18 07:01:04
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -76.05%
Max. DrawDown Benchmark -8.41%

This Long-Short strategy aims to find promising assets to invest in for a maximum holding period of 3 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 15.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

For Long-Short model portfolios, the short-selling costs (asset borrowing costs) are not taken into account. This assumption is likely unrealistic, and it is important to understand the short-selling process before employing this type of strategy.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
4

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 10% -9.54%
UTMD Utah Medical Products, Inc. Sell -5.16% 0.42%
AADI Aadi Bioscience, Inc. Sell -4.64% 10.38%
The percentage of cash held in the portfolio is: 99.8%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-18 00:00:00 : Portfolio change date
Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 10% -9.54%
UTMD Utah Medical Products, Inc. Sell -5.16% 0.42%
AADI Aadi Bioscience, Inc. Sell -4.64% 10.38%
The percentage of cash held in the portfolio is: 99.8%
New Assets Added
None
Assets Removed
Asset Action Perf %
HROW Buy All NA
Assets Rebalanced
None
2025-02-10 00:00:00 : Portfolio change date
Asset Action Weight PnL
RGNX REGENXBIO Inc. Buy 11.15% 1.73%
HROW Harrow Health, Inc. Sell -6.75% 3.96%
UTMD Utah Medical Products, Inc. Sell -5.01% 2.37%
AADI Aadi Bioscience, Inc. Sell -4.92% 4.15%
The percentage of cash held in the portfolio is: 105.54%
New Assets Added
None
Assets Removed
Asset Action Perf %
BLFS Sell All -7.77%
Assets Rebalanced
None
2025-02-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLFS BioLife Solutions, Inc. Buy 15.96% -7.46%
RGNX REGENXBIO Inc. Buy 11.42% 4.46%
HROW Harrow Health, Inc. Sell -6.74% 3.87%
UTMD Utah Medical Products, Inc. Sell -5.01% 2.3%
AADI Aadi Bioscience, Inc. Sell -5.02% 2.08%
The percentage of cash held in the portfolio is: 89.39%
New Assets Added
None
Assets Removed
Asset Action Perf %
HAE Buy All 14.33%
ORGO Sell All 6.61%
NUTX Sell All 54.16%
Assets Rebalanced
None
2025-02-06 00:00:00 : Portfolio change date
Asset Action Weight PnL
ORGO Organogenesis Holdings Inc. Buy 11.75% 8.11%
NUTX Nutex Health Inc. Buy 15.55% 42.68%
BLFS BioLife Solutions, Inc. Buy 16.55% -5.58%
RGNX REGENXBIO Inc. Buy 11.61% 4.46%
HAE Haemonetics Corporation Sell -6.92% 3.11%
HROW Harrow Health, Inc. Sell -6.82% 4.34%
UTMD Utah Medical Products, Inc. Sell -5.1% 2.14%
AADI Aadi Bioscience, Inc. Sell -5.23% -0.35%
The percentage of cash held in the portfolio is: 68.6%
New Assets Added
None
Assets Removed
Asset Action Perf %
MDXG Sell All -3.17%
MD Sell All -0.14%
Assets Rebalanced
None
2025-02-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
MDXG MiMedx Group, Inc. Buy 11.52% -3.06%
MD Pediatrix Medical Group, Inc. Buy 11.51% -0.64%
ORGO Organogenesis Holdings Inc. Buy 11.58% 4.5%
NUTX Nutex Health Inc. Buy 14.05% 26.47%
BLFS BioLife Solutions, Inc. Buy 16.63% -6.96%
RGNX REGENXBIO Inc. Buy 11.83% 4.46%
HAE Haemonetics Corporation Sell -6.83% 6.27%
HROW Harrow Health, Inc. Sell -6.94% 4.52%
UTMD Utah Medical Products, Inc. Sell -5.19% 2.17%
AADI Aadi Bioscience, Inc. Sell -5.02% 5.54%
The percentage of cash held in the portfolio is: 46.85%
New Assets Added
None
Assets Removed
Asset Action Perf %
MDRX Buy All 47.11%
ACRS Sell All 0.4%
Assets Rebalanced
None
2025-02-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
ACRS Aclaris Therapeutics, Inc. Buy 11.44% -4%
MDXG MiMedx Group, Inc. Buy 11.63% -3.17%
MD Pediatrix Medical Group, Inc. Buy 11.63% -0.57%
ORGO Organogenesis Holdings Inc. Buy 11.46% 2.4%
NUTX Nutex Health Inc. Buy 14.29% 27.3%
BLFS BioLife Solutions, Inc. Buy 16.99% -5.94%
RGNX REGENXBIO Inc. Buy 11.09% -3.1%
HAE Haemonetics Corporation Sell -6.62% 10.04%
MDRX Allscripts Healthcare Solutions, Inc. Sell -3.55% 44.44%
HROW Harrow Health, Inc. Sell -6.79% 7.62%
UTMD Utah Medical Products, Inc. Sell -5.24% 2.27%
AADI Aadi Bioscience, Inc. Sell -5.09% 5.19%
The percentage of cash held in the portfolio is: 38.75%
New Assets Added
None
Assets Removed
Asset Action Perf %
INSM Sell All 12.98%
AXGN Sell All -1.81%
SIGA Sell All -9.55%
Assets Rebalanced
None
2025-02-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 11.54% 11.1%
AXGN AxoGen, Inc. Buy 12.87% -0.22%
ACRS Aclaris Therapeutics, Inc. Buy 11.69% -0.8%
MDXG MiMedx Group, Inc. Buy 11.71% -1.36%
MD Pediatrix Medical Group, Inc. Buy 11.55% -0.14%
ORGO Organogenesis Holdings Inc. Buy 12.23% 10.51%
NUTX Nutex Health Inc. Buy 13.72% 23.71%
SIGA SIGA Technologies, Inc. Buy 12.31% -6.42%
BLFS BioLife Solutions, Inc. Buy 17.22% -3.5%
RGNX REGENXBIO Inc. Buy 11.31% 0%
HAE Haemonetics Corporation Sell -6.83% 6.09%
MDRX Allscripts Healthcare Solutions, Inc. Sell -3.83% 39.33%
HROW Harrow Health, Inc. Sell -6.91% 4.86%
UTMD Utah Medical Products, Inc. Sell -5.29% 0.13%
AADI Aadi Bioscience, Inc. Sell -5.28% 0.35%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • RGNX
Assets Removed
Asset Action Perf %
TGTX Sell All -0.69%
Assets Rebalanced
None
2025-01-30 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 11.77% 13.16%
AXGN AxoGen, Inc. Buy 12.95% 0.33%
ACRS Aclaris Therapeutics, Inc. Buy 11.13% -5.6%
MDXG MiMedx Group, Inc. Buy 12.19% 2.61%
MD Pediatrix Medical Group, Inc. Buy 11.73% 1.36%
ORGO Organogenesis Holdings Inc. Buy 12.64% 14.11%
NUTX Nutex Health Inc. Buy 12.91% 16.31%
SIGA SIGA Technologies, Inc. Buy 12.9% -2.03%
TGTX TG Therapeutics, Inc. Buy 11.92% 4.54%
BLFS BioLife Solutions, Inc. Buy 17.86% 0%
HAE Haemonetics Corporation Sell -6.76% 7.13%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.35% 15.44%
HROW Harrow Health, Inc. Sell -7.28% -0.19%
UTMD Utah Medical Products, Inc. Sell -5.31% 0%
AADI Aadi Bioscience, Inc. Sell -5.31% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • UTMD
  • AADI
  • BLFS
Assets Removed
Asset Action Perf %
ORMP Buy All 5.46%
AORT Sell All 3.27%
Assets Rebalanced
None
2025-01-29 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.72% 2.68%
INSM Insmed Incorporated Buy 12.01% 13.83%
AXGN AxoGen, Inc. Buy 13.21% 0.88%
ACRS Aclaris Therapeutics, Inc. Buy 11.44% -4.4%
MDXG MiMedx Group, Inc. Buy 12.38% 2.72%
MD Pediatrix Medical Group, Inc. Buy 12.13% 3.29%
ORGO Organogenesis Holdings Inc. Buy 12.01% 6.91%
NUTX Nutex Health Inc. Buy 12.52% 11.14%
SIGA SIGA Technologies, Inc. Buy 12.96% -2.97%
TGTX TG Therapeutics, Inc. Buy 12.12% 4.79%
ORMP Oramed Pharmaceuticals Inc. Sell -5.31% 5.46%
HAE Haemonetics Corporation Sell -6.92% 6.31%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.7% 11.11%
HROW Harrow Health, Inc. Sell -7.46% -1.27%
The percentage of cash held in the portfolio is: 2.9%
New Assets Added
None
Assets Removed
Asset Action Perf %
FATE Buy All 25.71%
Assets Rebalanced
Asset Action Weight
TGTX Sell -7.88%
AXGN Buy 0.48%
SIGA Buy 0.79%
2025-01-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.73% 1.36%
AXGN AxoGen, Inc. Buy 11.7% -1.75%
INSM Insmed Incorporated Buy 12.04% 12.62%
ACRS Aclaris Therapeutics, Inc. Buy 11.88% -2%
MD Pediatrix Medical Group, Inc. Buy 12.48% 4.86%
MDXG MiMedx Group, Inc. Buy 12.06% -1.25%
ORGO Organogenesis Holdings Inc. Buy 12.79% 12.31%
NUTX Nutex Health Inc. Buy 12% 5.09%
SIGA SIGA Technologies, Inc. Buy 11.97% -0.78%
TGTX TG Therapeutics, Inc. Buy 19.35% 0%
FATE Fate Therapeutics, Inc. Sell -4.48% 21.71%
ORMP Oramed Pharmaceuticals Inc. Sell -5.36% 5.88%
HAE Haemonetics Corporation Sell -7.26% 3.05%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.44% 16.33%
HROW Harrow Health, Inc. Sell -7.47% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HROW
  • TGTX
Assets Removed
Asset Action Perf %
ESPR Sell All -14.96%
Assets Rebalanced
None
2025-01-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.6% 1.42%
ESPR Esperion Therapeutics, Inc. Buy 12.37% -10.26%
AXGN AxoGen, Inc. Buy 11.7% -0.6%
INSM Insmed Incorporated Buy 12.04% 13.85%
ACRS Aclaris Therapeutics, Inc. Buy 12.04% 0.4%
MD Pediatrix Medical Group, Inc. Buy 12.04% 2.29%
MDXG MiMedx Group, Inc. Buy 12.04% -0.34%
ORGO Organogenesis Holdings Inc. Buy 12.04% 6.91%
NUTX Nutex Health Inc. Buy 12.47% 10.49%
SIGA SIGA Technologies, Inc. Buy 12.04% 0.94%
FATE Fate Therapeutics, Inc. Sell -4.3% 24%
ORMP Oramed Pharmaceuticals Inc. Sell -5.37% 4.62%
HAE Haemonetics Corporation Sell -7.13% 3.69%
MDRX Allscripts Healthcare Solutions, Inc. Sell -5.57% 13.33%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
TGTX Buy All -11.64%
Assets Rebalanced
Asset Action Weight
AXGN Sell -1.98%
ACRS Sell -1.81%
INSM Sell -3.64%
ORGO Sell -23.86%
NUTX Buy 1.71%
SIGA Buy 4.12%
MD Buy 9.28%
MDXG Buy 9.35%
2025-01-23 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 11.71% 1.82%
ESPR Esperion Therapeutics, Inc. Buy 13.02% -5.98%
AXGN AxoGen, Inc. Buy 14.33% 3.51%
INSM Insmed Incorporated Buy 15.75% 13.81%
ACRS Aclaris Therapeutics, Inc. Buy 14.42% 4%
MD Pediatrix Medical Group, Inc. Buy 2.72% 0.5%
MDXG MiMedx Group, Inc. Buy 2.76% 1.93%
ORGO Organogenesis Holdings Inc. Buy 35.47% 5.11%
NUTX Nutex Health Inc. Buy 9.3% -1.01%
SIGA SIGA Technologies, Inc. Buy 7.88% 0%
TGTX TG Therapeutics, Inc. Sell -5.99% -4.07%
FATE Fate Therapeutics, Inc. Sell -4.35% 23.43%
ORMP Oramed Pharmaceuticals Inc. Sell -5.49% 2.94%
HAE Haemonetics Corporation Sell -7.42% 0.24%
MDRX Allscripts Healthcare Solutions, Inc. Sell -6.12% 5.33%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • SIGA
Assets Removed
Asset Action Perf %
BLUE Sell All -20.97%
Assets Rebalanced
None
2025-01-22 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 8.2% -17.94%
AORT Artivion, Inc. Buy 12.03% 4.5%
ESPR Esperion Therapeutics, Inc. Buy 12.74% -8.12%
AXGN AxoGen, Inc. Buy 14.41% 3.95%
INSM Insmed Incorporated Buy 15.43% 11.34%
ACRS Aclaris Therapeutics, Inc. Buy 14.44% 4%
MD Pediatrix Medical Group, Inc. Buy 2.71% 0%
MDXG MiMedx Group, Inc. Buy 2.81% 3.63%
ORGO Organogenesis Holdings Inc. Buy 35.82% 6.01%
NUTX Nutex Health Inc. Buy 9.41% 0%
TGTX TG Therapeutics, Inc. Sell -6.15% -6.64%
FATE Fate Therapeutics, Inc. Sell -4.29% 24.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.47% 3.36%
HAE Haemonetics Corporation Sell -7.62% -2.33%
MDRX Allscripts Healthcare Solutions, Inc. Sell -6.47% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MDRX
  • NUTX
Assets Removed
Asset Action Perf %
APLS Buy All -9.8%
TNDM Sell All -5.5%
Assets Rebalanced
None
2025-01-17 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 8.49% -16.73%
TNDM Tandem Diabetes Care, Inc. Buy 10.24% 0.47%
AORT Artivion, Inc. Buy 12.14% 3.34%
ESPR Esperion Therapeutics, Inc. Buy 13.67% -3.42%
AXGN AxoGen, Inc. Buy 14.28% 0.99%
INSM Insmed Incorporated Buy 14.92% 5.54%
ACRS Aclaris Therapeutics, Inc. Buy 14.22% 0.4%
MD Pediatrix Medical Group, Inc. Buy 2.72% -1.64%
MDXG MiMedx Group, Inc. Buy 2.85% 2.95%
ORGO Organogenesis Holdings Inc. Buy 34.48% 0%
TGTX TG Therapeutics, Inc. Sell -6.12% -4.07%
FATE Fate Therapeutics, Inc. Sell -4.15% 28.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.63% 2.52%
APLS Apellis Pharmaceuticals, Inc. Sell -6.51% -8.35%
HAE Haemonetics Corporation Sell -7.6% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HAE
  • ORGO
Assets Removed
Asset Action Perf %
NUTX Buy All -22.6%
MDRX Sell All -6.56%
Assets Rebalanced
None
2025-01-16 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 8.86% -16.43%
TNDM Tandem Diabetes Care, Inc. Buy 10.21% -3.76%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.85% -4.51%
AORT Artivion, Inc. Buy 12.15% -0.56%
ESPR Esperion Therapeutics, Inc. Buy 13.91% -5.56%
AXGN AxoGen, Inc. Buy 15.1% 2.63%
INSM Insmed Incorporated Buy 14.99% 1.84%
ACRS Aclaris Therapeutics, Inc. Buy 14.8% 0.4%
MD Pediatrix Medical Group, Inc. Buy 2.88% 0%
MDXG MiMedx Group, Inc. Buy 2.88% 0%
TGTX TG Therapeutics, Inc. Sell -6.59% -7.79%
FATE Fate Therapeutics, Inc. Sell -4.56% 24.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.91% 1.68%
NUTX Nutex Health Inc. Sell 15.05% -5.86%
APLS Apellis Pharmaceuticals, Inc. Sell -6.61% -5.79%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • MD
  • MDXG
Assets Removed
Asset Action Perf %
ARDX Sell All 0.19%
Assets Rebalanced
None
2025-01-15 00:00:00 : Portfolio change date
Asset Action Weight PnL
BLUE bluebird bio, Inc. Buy 8.61% -19.25%
TNDM Tandem Diabetes Care, Inc. Buy 10.21% -4.19%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.66% -6.67%
AORT Artivion, Inc. Buy 12.06% -1.82%
ARDX Ardelyx, Inc. Buy 12.93% 5.24%
ESPR Esperion Therapeutics, Inc. Buy 14.17% -4.27%
AXGN AxoGen, Inc. Buy 14.78% -0.05%
INSM Insmed Incorporated Buy 14.65% -0.93%
ACRS Aclaris Therapeutics, Inc. Buy 14.81% 0%
NUTX Nutex Health Inc. Sell 14.81% -3.63%
TGTX TG Therapeutics, Inc. Sell -6.53% -6.21%
FATE Fate Therapeutics, Inc. Sell -4.34% 28.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.99% 0.84%
APLS Apellis Pharmaceuticals, Inc. Sell -6.34% -0.91%
The percentage of cash held in the portfolio is: -4.51%
New Assets Added
  • NUTX
  • ACRS
Assets Removed
None
Assets Rebalanced
None
2025-01-14 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 10.1% -3.07%
BLUE bluebird bio, Inc. Buy 8.92% -14.42%
MDRX Allscripts Healthcare Solutions, Inc. Buy 10.88% -2.56%
AORT Artivion, Inc. Buy 11.65% -2.94%
ARDX Ardelyx, Inc. Buy 13.22% 10.11%
ESPR Esperion Therapeutics, Inc. Buy 14.09% -2.56%
AXGN AxoGen, Inc. Buy 14.46% 0%
INSM Insmed Incorporated Buy 14.46% 0%
TGTX TG Therapeutics, Inc. Sell -5.94% 1.18%
FATE Fate Therapeutics, Inc. Sell -4.37% 26.29%
ORMP Oramed Pharmaceuticals Inc. Sell -5.86% 0.84%
NUTX Nutex Health Inc. Sell -6.12% 0.39%
APLS Apellis Pharmaceuticals, Inc. Sell -6.4% -4.19%
The percentage of cash held in the portfolio is: 30.91%
New Assets Added
  • AXGN
  • INSM
Assets Removed
None
Assets Rebalanced
None
2025-01-13 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 10.25% -3.63%
BLUE bluebird bio, Inc. Buy 9.07% -14.72%
MDRX Allscripts Healthcare Solutions, Inc. Buy 11.11% -2.46%
AORT Artivion, Inc. Buy 12.11% -1.16%
ARDX Ardelyx, Inc. Buy 11.64% -5.06%
ESPR Esperion Therapeutics, Inc. Buy 14.76% 0%
TGTX TG Therapeutics, Inc. Sell -6.33% -3.14%
FATE Fate Therapeutics, Inc. Sell -5.09% 16%
ORMP Oramed Pharmaceuticals Inc. Sell -6.05% -0.42%
NUTX Nutex Health Inc. Sell -6.27% 0%
APLS Apellis Pharmaceuticals, Inc. Sell -6.27% 0%
The percentage of cash held in the portfolio is: 61.06%
New Assets Added
  • NUTX
  • APLS
  • ESPR
Assets Removed
None
Assets Rebalanced
None
2025-01-09 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 10.61% 0.36%
BLUE bluebird bio, Inc. Buy 9.02% -14.72%
MDRX Allscripts Healthcare Solutions, Inc. Buy 11.05% -2.46%
AORT Artivion, Inc. Buy 12.19% 0%
ARDX Ardelyx, Inc. Buy 12.19% 0%
TGTX TG Therapeutics, Inc. Sell -6.27% -2.75%
FATE Fate Therapeutics, Inc. Sell -5.75% 4.57%
ORMP Oramed Pharmaceuticals Inc. Sell -5.99% 0%
The percentage of cash held in the portfolio is: 62.95%
New Assets Added
  • ORMP
  • AORT
  • ARDX
Assets Removed
None
Assets Rebalanced
None
2025-01-08 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 10.42% -0.82%
BLUE bluebird bio, Inc. Buy 9.55% -9.07%
MDRX Allscripts Healthcare Solutions, Inc. Buy 11.26% 0%
TGTX TG Therapeutics, Inc. Sell -6.06% 0%
FATE Fate Therapeutics, Inc. Sell -5.98% 0%
The percentage of cash held in the portfolio is: 80.81%
New Assets Added
  • FATE
  • MDRX
Assets Removed
None
Assets Rebalanced
None
2025-01-07 00:00:00 : Portfolio change date
Asset Action Weight PnL
TNDM Tandem Diabetes Care, Inc. Buy 10.4% 0%
BLUE bluebird bio, Inc. Buy 10.4% 0%
TGTX TG Therapeutics, Inc. Sell -6% 0%
The percentage of cash held in the portfolio is: 85.2%
New Assets Added
  • TGTX
  • TNDM
  • BLUE
Assets Removed
None
Assets Rebalanced
None
2024-12-26 00:00:00 : Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is: 100%
New Assets Added
None
Assets Removed
Asset Action Perf %
PCRX Sell All NA
Assets Rebalanced
None
2024-12-25 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 13.2% 1.99%
The percentage of cash held in the portfolio is: 86.8%
New Assets Added
None
Assets Removed
Asset Action Perf %
CUTR Buy All 19.51%
NKTR Buy All 14.95%
FATE Buy All 36.88%
Assets Rebalanced
None
2024-12-23 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 13% -0.58%
CUTR Cutera, Inc. Sell -5.83% 12.2%
NKTR Nektar Therapeutics Sell -5.77% 13.08%
FATE Fate Therapeutics, Inc. Sell -4.24% 36.12%
The percentage of cash held in the portfolio is: 102.85%
New Assets Added
None
Assets Removed
Asset Action Perf %
IBRX Buy All 48.02%
Assets Rebalanced
None
2024-12-18 00:00:00 : Portfolio change date
Asset Action Weight PnL
PCRX Pacira BioSciences, Inc. Buy 13.66% 3.88%
IBRX ImmunityBio, Inc. Sell -3.58% 43.85%
CUTR Cutera, Inc. Sell -5.7% 14.63%
NKTR Nektar Therapeutics Sell -6.37% 4.67%
FATE Fate Therapeutics, Inc. Sell -4.78% 28.52%
The percentage of cash held in the portfolio is: 106.77%
New Assets Added
None
Assets Removed
Asset Action Perf %
APLS Sell All 5.82%
MGNX Sell All -1.76%
Assets Rebalanced
None
2024-12-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 13.02% 4.2%
MGNX MacroGenics, Inc. Buy 12.53% 0.29%
PCRX Pacira BioSciences, Inc. Buy 14.14% 6.5%
IBRX ImmunityBio, Inc. Sell -4.03% 37.5%
CUTR Cutera, Inc. Sell -5.92% 12.2%
NKTR Nektar Therapeutics Sell -6.43% 4.67%
FATE Fate Therapeutics, Inc. Sell -5.59% 17.11%
The percentage of cash held in the portfolio is: 82.28%
New Assets Added
None
Assets Removed
Asset Action Perf %
ESPR Sell All -13.23%
Assets Rebalanced
None
2024-12-10 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 13.4% 7.32%
MGNX MacroGenics, Inc. Buy 12.78% 2.35%
ESPR Esperion Therapeutics, Inc. Buy 12.94% 23.55%
PCRX Pacira BioSciences, Inc. Buy 13.27% 0%
IBRX ImmunityBio, Inc. Sell -6.13% 4.76%
CUTR Cutera, Inc. Sell -6.08% 9.76%
NKTR Nektar Therapeutics Sell -6.36% 5.61%
FATE Fate Therapeutics, Inc. Sell -6.97% -3.42%
The percentage of cash held in the portfolio is: 73.15%
New Assets Added
None
Assets Removed
Asset Action Perf %
PACB Buy All -23.86%
RVNC Sell All -27.34%
Assets Rebalanced
None
2024-12-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 12.75% 4.6%
MGNX MacroGenics, Inc. Buy 12.51% 2.65%
ESPR Esperion Therapeutics, Inc. Buy 12.07% 18.06%
RVNC Revance Therapeutics, Inc. Buy 12.95% 0%
PCRX Pacira BioSciences, Inc. Buy 12.95% 0%
PACB Pacific Biosciences of California, Inc. Sell -5.45% -18.18%
IBRX ImmunityBio, Inc. Sell -5.91% 5.95%
CUTR Cutera, Inc. Sell -6.9% -4.88%
NKTR Nektar Therapeutics Sell -6.27% 4.67%
FATE Fate Therapeutics, Inc. Sell -6.4% 2.66%
The percentage of cash held in the portfolio is: 67.7%
New Assets Added
  • RVNC
  • PCRX
Assets Removed
Asset Action Perf %
ARWR Sell All -11.63%
Assets Rebalanced
None
2024-12-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 12.84% 6.13%
MGNX MacroGenics, Inc. Buy 12.24% 1.18%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 11.77% -0.31%
ESPR Esperion Therapeutics, Inc. Buy 10.64% 4.84%
PACB Pacific Biosciences of California, Inc. Sell -4.76% -3.98%
IBRX ImmunityBio, Inc. Sell -5.65% 9.52%
CUTR Cutera, Inc. Sell -6.53% 0%
NKTR Nektar Therapeutics Sell -6.53% 0%
FATE Fate Therapeutics, Inc. Sell -6.53% 0%
The percentage of cash held in the portfolio is: 82.5%
New Assets Added
  • CUTR
  • NKTR
  • FATE
Assets Removed
None
Assets Rebalanced
None
2024-12-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 13.13% 8.55%
MGNX MacroGenics, Inc. Buy 13.13% 8.53%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 11.89% 0.73%
ESPR Esperion Therapeutics, Inc. Buy 10.15% 0%
PACB Pacific Biosciences of California, Inc. Sell -5.01% -9.66%
IBRX ImmunityBio, Inc. Sell -6.15% 1.39%
The percentage of cash held in the portfolio is: 62.87%
New Assets Added
  • ESPR
Assets Removed
Asset Action Perf %
FATE Sell All -6.62%
Assets Rebalanced
None
2024-12-02 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 12.62% 3.98%
MGNX MacroGenics, Inc. Buy 12.81% 5.59%
ARWR Arrowhead Pharmaceuticals, Inc. Buy 11.78% -0.46%
FATE Fate Therapeutics, Inc. Buy 11.84% 0%
PACB Pacific Biosciences of California, Inc. Sell -4.98% -8.52%
IBRX ImmunityBio, Inc. Sell -6.26% 0%
The percentage of cash held in the portfolio is: 62.19%
New Assets Added
  • IBRX
Assets Removed
Asset Action Perf %
CUTR Buy All -25.64%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings